Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma

British Journal of Haematology

Volumn 164, Issue 5, 2014, Pages 750-752

  Chaoui, Driss ^a   Bouallegue, Sonia ^a   Arakelyan, Nina ^a   Genet, Philippe ^a   Aljijakli, Ahmad ^a   Sutton, Laurent ^a  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

Angioimmunoblastic T cell lymphoma; Bortezomib; Lenalidomide

Indexed keywords

AGED; AGED, 80 AND OVER; BORONIC ACIDS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; PYRAZINES; SALVAGE THERAPY; THALIDOMIDE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84894064516     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12678     Document Type: Article

References (10)

1. Damaj, G., Gressin, R., Bouabdallah, K., Cartron, G., Choufi, B., Gyan, E., Banos, A., Jaccard, A., Park, S., Tournilhac, O., Schiano-de Collela, J.M., Voillat, L., Joly, B., Le Gouill, S., Saad, A., Cony-Makhoul, P., Vilque, J.P., Sanhes, L., Schmidt-Tanguy, A., Bubenheim, M., Houot, R., Diouf, M., Marolleau, J.P., Béné, M.C., Martin, A. & Lamy, T. (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. Journal of Clinical Oncology, 31, 104-110.
2. Delfau-Larue, M.H., de Leval, L., Joly, B., Plonquet, A., Challine, D., Parrens, M., Delmer, A., Salles, G., Morschhauser, F., Delarue, R., Brice, P., Bouabdallah, R., Casasnovas, O., Tilly, H., Gaulard, P. & Haioun, C. (2012) Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica, 97, 1594-1602.
3. Evens, A.M., Rosen, S.T., Helenowski, I., Klin, J., Larsen, A., Colvin J., Winter, W.J., van Besien, K.M., Leo, I., Gordon, L.I. & Smith, S.M. (2013) A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. British Journal of Haematology, 163, 55-61.
4. Federico, M., Rudiger, T., Bellei, M., Nathwani, B.N., Luminari, S., Coiffier, B., Harris, N.L., Jaffe, E.S., Pileri, S.A., Savage, K.J., Weisenburger, D.D., Armitage, J.O., Mounier, N. & Vose, J.M. (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. Journal of Clinical Oncology, 31, 240-246.
5. Lentzsch, S., LeBlanc, R., Podar, K., DaviesM, F., Lin, B., Hideshima, T., Catley, L., Stirling, D.I. & Anderson, K.C. (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia, 17, 41-44.
6. Leval, D., Gisselbrecht, C. & Gaulard, P. (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. British Journal of Haematolology, 148, 673-689.
7. Liu, S., Yuan, Z., Zhang, C., Fu, W. & Hou, J. (2012) Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: case report and literature review. Oncology Letters, 4, 262-264.
8. ®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. European Journal of Cancer, 49, 2869-2876.
9. Mourad, N., Mounier, N., Brière, J., Raffoux, E., Delmer, A., Feller, A., Meijer, C.J., Emile, J.F., Bouabdallah, R., Bosly, A., Diebold, J., Haioun, C., Coiffier, B., Gisselbrecht, C. & Gaulard, P.; Groupe d'Etude des Lymphomes de l'Adulte. (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood, 111, 4463-4470.
10. Ri, M., Iida, S., Ishida, T., Ito, A., Yano, H., Inagaki, A., Ding, J., Kusumoto, S., Komatsu, H., Utsunomiya, A. & Ueda, R. (2009) Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Science, 100, 341-348.